D-vítamín gagnast gegn Covid-19 samkvæmt rannsóknum. Mildar einkenni og bætir lífslíkur sjúklinga

Undanfarið hafa birst rannsóknir um virkni D-vítamíns gegn Covid19 og niðurstöður þeirra benda eindregið til þess að sjúklingar með lág gildi D-vítamíns fái mun erfiðari sjúkdóm en þeir sem eru með nægt D-vítamín í blóði.

Rannsóknir sýna einnig að D-vítamín skortur er útbreitt vandamál, jafnvel í sólríkum löndum. Hér eru nokkrar nýlegar rannsóknir:

Vitamin D Deficiency Is Inversely Associated with COVID-19 Incidence and Disease Severity in Chinese People. 13. nóvember 2020 :

“These findings suggested that vitamin D deficiency impacts COVID-19 hospitalization and severity in the Chinese population.”

Vitamin D and survival in COVID-19 patients: A quasi-experimental study. 13. október 2020: 

“In conclusion, bolus vitamin D3 supplementation during or just before COVID-19 was associated in frail elderly with less severe COVID-19 and better survival rate.”

Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results. 23. september 2020 :

“In this cohort study of 489 patients who had a vitamin D level measured in the year before COVID-19 testing, the relative risk of testing positive for COVID-19 was 1.77 times greater for patients with likely deficient vitamin D status compared with patients with likely sufficient vitamin D status, a difference that was statistically significant.”

Vitamin D Deficiency and Outcome of COVID-19 Patients. 10. september 2020:

“Our study demonstrates an association between VitD deficiency and severity/mortality of COVID-19”

Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study. 29. ágúst 2020 : 

“Our pilot study demonstrated that administration of a high dose of Calcifediol or 25-hydroxyvitamin D, a main metabolite of vitamin D endocrine system, significantly reduced the need for ICU treatment of patients requiring hospitalization due to proven COVID-19. Calcifediol seems to be able to reduce severity of the disease, but larger trials with groups properly matched will be required to show a definitive answer.”

Viðbót 13. nóvember: Vísindamenn hjá MIT háskóla hafa nú rannsakað gögn úr ofangreindri rannsókn og staðfest ályktanir.

Low plasma 25(OH) vitamin D level is associated with increased risk of COVID‐19 infection: an Israeli population‐based study. 23 júlí 2020: 

“We concluded that low plasma 25(OH)D levels appear to be an independent risk factor for COVID‐19 infection and hospitalization. ”We concluded that low plasma 25(OH)D levels appear to be an independent risk factor for COVID‐19 infection and hospitalization.”

SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. 17. sept 2020: 

“SARS-CoV-2 positivity is strongly and inversely associated with circulating 25(OH)D levels, a relationship that persists across latitudes, races/ethnicities, both sexes, and age ranges.”

Fleiri rannsóknargreinar um virkni D-vítamíns gegn Covid19 má finna hér.

Hvað þarf að taka mikið af D vítamíni til að vera með nóg?

Á norðlægum slóðum getur húðin ekki unnið nægt D-vítamín úr sólarljósi nema rétt yfir sumarmánuðina. Ekki er mögulegt að fá nægt D-vítamín úr venjulegum mat og ekki fæst nóg D þótt tekið sé lýsi daglega. Því þarf að taka D vítamín sem bætiefni. Fullorðnum nægir yfirleitt að taka 2-4.000 AE (AE er sama eining og IU) eða 250 mcg af D3 daglega. Ekki er ráðlagt að taka stærri skammta í marga daga nema í samráði við lækni.